Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Thrombogenic Factors and Recurrent Coronary Events

This study has been completed.
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by:
University of Rochester Identifier:
First received: May 25, 2000
Last updated: January 14, 2016
Last verified: January 2016
To determine if selected circulating blood factors that reflect enhanced thrombogenesis are associated with an increased incidence of recurrent coronary events, including cardiac death or non-fatal myocardial infarction.

Cardiovascular Diseases
Heart Diseases
Coronary Disease
Myocardial Infarction
Death, Sudden, Cardiac

Study Type: Observational

Resource links provided by NLM:

Further study details as provided by University of Rochester:

Study Start Date: April 1994
Estimated Study Completion Date: March 1999
Detailed Description:


In this multicenter, collaborative, prospective study, patients hospitalized with a myocardial infarction were enrolled from ten geographically dispersed centers. Five thrombogenic- related blood factors were quantitated, and formed the centerpiece of this study: 1) lipoprotein(a) [Lp(a)] - a quantitative genetic factor that contains apolipoprotein B, has a structural homology to plasminogen, interferes with intrinsic thrombolytic activity, and represents a crossover link in the thrombogenesis/atherogenesis hypothesis; 2) soluble fibrin - a system indicator of coagulation activity in the ongoing conversion of fibrinogen to insoluble fibrin strands; 3) plasminogen activator inhibitor-1 (PAI-1) - an important regulator of the fibrinolytic system, it interferes with intrinsic t-PA activity; 4) coagulation Factor VII -high levels lead to increased thrombogenesis and have been associated with an increased risk of ischemic heart disease; and- 5) von Willebrand factor - it binds to platelet glycoproteins, contributes to local thrombus formation, and it is elevated in patients at increased risk of coronary thrombosis.

The primary analysis utilized a time-dependent survivors hip model (Cox regression) to determine the presence or absence of an association between one or more of these factors and subsequent thrombotic-related coronary events. Secondary objectives included: 1) to determine if there was a statistical association between the thrombogenic factors and conventional hematologic/lipid parameters, and to evaluate their interactions regarding coronary events; and 2) to determine if thrombogenic factors had uniform effects on coronary event rates across various subgroups.


Ages Eligible for Study:   up to 100 Years   (Child, Adult, Senior)
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
No eligibility criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00005358

Sponsors and Collaborators
University of Rochester
National Heart, Lung, and Blood Institute (NHLBI)
OverallOfficial: Arthur Moss University of Rochester
  More Information

Publications: Identifier: NCT00005358     History of Changes
Other Study ID Numbers: 4245  R01HL048259 
Study First Received: May 25, 2000
Last Updated: January 14, 2016
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cardiovascular Diseases
Heart Diseases
Myocardial Infarction
Coronary Disease
Coronary Artery Disease
Death, Sudden
Death, Sudden, Cardiac
Pathologic Processes
Myocardial Ischemia
Vascular Diseases
Embolism and Thrombosis
Arterial Occlusive Diseases
Heart Arrest processed this record on October 21, 2016